Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc. (DMAC) Stock Ticker

NASDAQ: DMAC · Healthcare · Biotechnology
$7.94+1.40%
USD · as of 2026-09-28 · market cap $427.8M
Open DMAC in TickrDownload for iPhone

DMAC right now

20% of the float is sold short.
Options expect by Oct 6±13.0%
Options expect by Oct 29±26.9%
Priced in for Nov 11 earnings±32.3%
IV rank (30-day)66% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full DMAC picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on DMAC
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

DMAC stock facts

Ticker symbolDMAC
ExchangeNASDAQ Capital Market
SectorHealthcare
IndustryBiotechnology
Market cap$427.8M
CEODietrich John Pauls
Employees35
HeadquartersMinneapolis, MN, US
IPO date2012-08-03
Websitewww.diamedica.com

What you can see for DMAC on Tickr

Live DMAC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DMAC report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for DiaMedica Therapeutics Inc.?

The ticker symbol for DiaMedica Therapeutics Inc. is DMAC, listed on the NASDAQ Capital Market.

What is DMAC?

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2…

HomeExploreMarketLists
All pages